The Medical College of Wisconsin - Endocrinology
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Obeidat, Ahmed
CELLO, NCT04877457: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

Terminated
4
3
US
Ocrelizumab, Placebo
Yale University, Genentech, Inc.
Radiologically Isolated Syndrome, Multiple Sclerosis
06/23
06/23
CLOCK-MS, NCT03963375: Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

Active, not recruiting
4
47
US
Cladribine
Washington University School of Medicine, EMD Serono
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
05/25
05/25
SOSTOS, NCT05090371: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Recruiting
4
150
Canada, US
Ofatumumab, Disease modifying treatment (DMT)
Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
12/26
12/26
NEOS, NCT04926818 / 2020-002700-39: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Active, not recruiting
3
129
Europe, Canada, US, RoW
Fingolimod, FTY720, Ofatumumab, OMB157, Siponimod, BAF312, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis (MS)
03/27
11/31
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
NCT06587828: A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease

Recruiting
N/A
300
US
Companion blood samples with procedure
TScan Therapeutics, Inc.
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (nr-axSpA), Crohn's Disease, Birdshot Chorioretinitis
01/25
06/25
MASTER-2, NCT03933202: A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS

Active, not recruiting
N/A
295
US
Cladribine Tablets
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
05/25
05/25
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26

Download Options